An engineered specificity of Irinotecan loaded Proniosomes: Design and Characterization
Keywords:
Pharmaceutics, Drug DeliveryAbstract
The aim of this investigation was to prepare, characterize and optimize the irinotecan loaded proniosomes for overall improvement in the efficacy, reduced toxicity and enhancement of therapeutic index of irinotecan. Proniosomes of Irinotecan hydrochloride trihydrate were prepared by slurry method using different surfactants, cholesterol and dicetyl phosphate. The formulations were then characterized with respect to shape and surface morphology, entrapment efficiency, invitro drug release profile, invivo drug targeting studies and stability under specific conditions. The formulated proniosomes were smoother indicating a thin and uniform coating over maltodextrin powder. The highest entrapment efficiency was found in formulation F4 with 74.23±3.1%. Highest cumulative percent drug release was observed with formulation F1 with 98.19% in 24 h. The in vivo result of formulated proniosomes of Irinotecan hydrochloride trihydrate reveals that the drug is preferentially targeting to liver followed by lungs and spleen. The results of investigation demonstrated that proniosomes offers an alternative colloidal carrier approach in achieving drug targeting. The results obtained for the present study clearly revealed that proniosomes containing irinotecan are retained at targeted sites and are capable of releasing there drug for the extended period of time.
References
Vyas SP, Singh RP, Jain S, Mishra V, Mahor S, Singh P. 2005. Nonionic surfactant based vesicles (niosomes) for non-invasive topical genetic immunization against hepatitis B. Int J Pharm., 296,80-6.
Mangit C, Kawakami S, Nishikawa M, Hashida M. 2003.Targeted and sustained drug delivery using PEGlyated galactosylated liposomes. Int J Pharm., 266,77-84.
Dufes C, gaillard F, Uchegbu IF, Schatzlein AG, Olievier JC, Muller JM.2004. Glucose-targeted niosomes deliver vasoactive intestinal peptide (VIP) to the brain. Int J Pharm., 285,77-85.
Azmin MN , Florence AT , Handjani-vila RM ,Stewert JF, Vanlerberghe G. 1985.The effect of nonionic surfactant vesicle (niosome) entrapment on the absorption and distribution of methotrexate in mice. J. Pharm. Pharmacol.,37, 237-242.
Baillie AJ, Florence AT, Hume LR, Muirhead GT, Rogerson A. 1985. The preparation and
Properties of niosome nonionic surfactant vesicles. J .Pharm. Pharmacol., 37, 863-868.
Hu C, Rhodes DG. 1999. Proniosomes: A novel drug carrier preparation. Int J Pharm.,
,23-35.
Almira I, Blazek W, Rhodes DG. 2001. Maltodextrin based proniosomes. AAPS
PharmSciTech., 3 (1), 1-7.
Charles F. 2006. Irinotecan in the treatment of colorectal Cancer. Cancer Treatment
Reviews., 32, 1283-87.
Martindale. The complete drug reference. Antineoplastics.34 ed.London: Pharmaceutical
Press; 2005:564-65.
Varshosaz J, Pardakhty A, Baharanchi SM. Sorbiton monopalmitate based Proniosomes
for transdermal delivery of chlorpheniramine maleate. Drug Delivery. 2005; 12(2): 75-
Jacob JS. Characterization of delivery systems, Microscopy. In: Mathiowitz E. editor
Encyclopedia of controlled Drug Delivery vol 1.John Wiley & Sons, Inc. New York
: 242-3.
Liberman H, Lachman L, Schwartz J. Pharmaceutical dosage forms: Tablets, Vol II. 2nd
ed., New York: Marcel Dekker Inc.1990: 229.
Agarwal R, Katare OP, Vyas SP. 2001.Preparation and In vitro evaluation of
liposomal/niosomal delivery systems for antipsoriatic drug dithranol. Int J Pharm.,
, 43-52.
Vyas SP, Goswami SK, Singh R. 1995. Liposomes based nasal delivery system of
nifedipine:Development and characterization. Int J Pharm.,118,23-30.
Wang JX,Sun X,Zhang ZR. 2002.Enhanced brain targeting by synthesis of 31,5 1-fluoro-
-deoxyuridine and incorporation in to solid lipid nanoparticles.Eur J Pharm
Biopharm., 54,285-90.
Committee for the Purpose of Control and Supervision on Experiments on Animals.
CPCSEA guidelines for laboratory animal facility. Ind J Pharmacol. 2003; 35: 257-
Sacchi A, Gasparri A, Gallo Stampino C. 2006. A Synergistic antitumor activity of
cisplatin, paclitaxel and gemcitabine with tumor vasculature targeted tumor necrosis
factor-α. Clin Cancer Res., 12,175-82.
The European agency for the evaluation of medicinal products. Stability testing
guidelines:Stability testing of new drug substances and products.London:ICH Technical
Coordination, EMEA; 2003.Available from:http://www.emea.eu.int. (accessed 20 Dec
